Corporate Member Update: Takeda- New indication in a CML therapy

Takeda's ICLUSIG is now FDA-approved for the treatment of adult patients with chronic phase (CP-) chronic myeloid leukemia (CML) with resistance or intolerance to at least 2 prior TKIs. The dosing strategy and safety profiel have also been updated. Please read the following for additional information.

ICLUSIG New Indication Document

Or visit their website at https://www.iclusig.com/